In summary, our findings suggest that the best clinical independent predictive factors for targeted therapy of Chinese NSCLC patients with EGFR inhibitors include an ADC histology, a nonsmoking history, and a younger age (≤65); for Chinese CRC patients, those who are female, older (>50 year old), and have ADC histology may benefit from mAb-based molecularly targeted therapies. The gene discussed is EGFR; the disease is colorectal carcinoma.